Statt 106,99 €**
96,29 €
**Preis der gedruckten Ausgabe (Gebundenes Buch)

inkl. MwSt. und vom Verlag festgesetzt.
Sofort per Download lieferbar
  • Format: PDF

Obesity has become a major epidemic that now rivals smoking as a risk to public health. The ensuing epidemics of diabetes, vascular disease and other complications are set to overwhelm the healthcare systems of wealthy and poorer nations alike. The need for effective pharmacotherapy has never been greater. This book takes a new look at the many potential targets for drug development for regulation of body weight, placing them in the context of the chequered history of drug development for obesity and currently available therapies.
Potential peripheral and central nervous system targets are
…mehr

Produktbeschreibung
Obesity has become a major epidemic that now rivals smoking as a risk to public health. The ensuing epidemics of diabetes, vascular disease and other complications are set to overwhelm the healthcare systems of wealthy and poorer nations alike. The need for effective pharmacotherapy has never been greater. This book takes a new look at the many potential targets for drug development for regulation of body weight, placing them in the context of the chequered history of drug development for obesity and currently available therapies.

Potential peripheral and central nervous system targets are discussed in detail by authors with extensive knowledge and research experience in the science of body weight regulation, and its translation into effective therapies that will benefit patients. This book is of interest to clinicians, researchers in the field and members of the pharmaceutical industry who are interested in learning more about the current state of the art and future directions in the pharmacotherapy of obesity.

Rezensionen
From the reviews:
"This book attempts to give a clear update of this obesity research and is readily accessible to healthcare professionals. ... This is a welcome update to the field of obesity research and will be of use to healthcare professional and researchers ... ." (Steven T. Russell, Inflammopharmacology, Vol. 18, 2010)